NASDAQ:MRTX - Mirati Therapeutics Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$73.23 -2.12 (-2.81 %)
(As of 03/24/2019 04:00 PM ET)
Previous Close$73.23
Today's Range$73.10 - $76.00
52-Week Range$24.65 - $80.00
Volume443,756 shs
Average Volume728,278 shs
Market Capitalization$2.58 billion
P/E Ratio-22.96
Dividend YieldN/A
Beta2.12
Mirati Therapeutics, Inc., a clinical-stage oncology company, develops targeted therapeutics to address the genetic, epigenetic, and immunological promoters of cancer. The company is involved in developing sitravatinib, an oral spectrum-selective kinase inhibitor, which is in Phase II clinical for the treatment of solid tumor; and in Phase Ib clinical trial to treat non-small cell lung cancer (NCSLC) patients with CBL, chromosome 4q12, and RET genetic alterations, as well as mocetinostat, an orally administered spectrum-selective Class 1 histone deacetylase inhibitor that is in Phase II clinical trial in combination with durvalumab for the treatment of patients with NSCLC. Its preclinical development stage product candidate include KRAS G12C inhibitor program to address mutations and tumors. The company has a collaboration and license agreement with BeiGene, Ltd. to develop manufacture and commercialize sitravatinib. It also has collaboration with Astex Pharmaceuticals, Inc. and Merck & Co., Inc.; Array BioPharma, Inc.; and Bristol-Myers Squibb Company to develop and commercialize products. Mirati Therapeutics, Inc. is headquartered in San Diego, California.

Receive MRTX News and Ratings via Email

Sign-up to receive the latest news and ratings for MRTX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:MRTX
CUSIPN/A
Phone858-332-3410

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$12.93 million
Book Value$5.86 per share

Profitability

Net Income$-98,420,000.00

Miscellaneous

EmployeesN/A
Market Cap$2.58 billion
Next Earnings Date5/6/2019 (Estimated)
OptionableOptionable

Mirati Therapeutics (NASDAQ:MRTX) Frequently Asked Questions

What is Mirati Therapeutics' stock symbol?

Mirati Therapeutics trades on the NASDAQ under the ticker symbol "MRTX."

How were Mirati Therapeutics' earnings last quarter?

Mirati Therapeutics Inc (NASDAQ:MRTX) issued its quarterly earnings results on Tuesday, November, 6th. The biotechnology company reported ($0.85) EPS for the quarter, topping the Thomson Reuters' consensus estimate of ($0.87) by $0.02. View Mirati Therapeutics' Earnings History.

When is Mirati Therapeutics' next earnings date?

Mirati Therapeutics is scheduled to release their next quarterly earnings announcement on Monday, May 6th 2019. View Earnings Estimates for Mirati Therapeutics.

What price target have analysts set for MRTX?

11 brokers have issued twelve-month price targets for Mirati Therapeutics' shares. Their predictions range from $37.00 to $85.00. On average, they anticipate Mirati Therapeutics' stock price to reach $66.3750 in the next twelve months. This suggests that the stock has a possible downside of 9.4%. View Analyst Price Targets for Mirati Therapeutics.

What is the consensus analysts' recommendation for Mirati Therapeutics?

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Mirati Therapeutics in the last year. There are currently 3 hold ratings and 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Mirati Therapeutics.

What are Wall Street analysts saying about Mirati Therapeutics stock?

Here are some recent quotes from research analysts about Mirati Therapeutics stock:
  • 1. According to Zacks Investment Research, "Mirati Therapeutics, Inc. is a biopharmaceutical company. It engaged in the development of novel therapeutics for the treatment of cancer. Mirati Therapeutics, Inc., formerly known as MethylGene Inc., is based in Montreal, Canada. " (3/7/2019)
  • 2. Cantor Fitzgerald analysts commented, ": We are initiating coverage of Neutral rating and 12-month price target of $66/share. Mirati shares are +300% since +70% YTD. We believe that current Street estimates reflect high expectations around the novel KRASi asset, and do not fully appreciate potential clinical, regulatory and commercial risks associated with the lead asset sitravatinib. KRASi asset will remain the near-term focus where first clinical data from Amgen (Neutral, covered by A. Young) (by mid-19) and Mirati (in 2H19) will each garner huge investor interest." (3/4/2019)
  • 3. HC Wainwright analysts commented, "We derive our $65 price target from a sum-of-the-parts analysis based on probability-adjusted revenue forecasts for sitravatinib and mocetinostat. We use the net present value of our revenue forecast through 2027, apply a 50% probability of success (POS) for sitravatinib in combination with checkpoint inhibitors, a 45% POS for sitravatinib monotherapy, 15% POS for mocetinostat, our YE2018 fully diluted net cash estimate of $4.79/share, and we value the early stage pipeline at $5.38/ share to arrive at our price target. We assume a 20% discount rate for the NPV of the pipeline and a P/S multiple of 4x." (11/12/2018)

Has Mirati Therapeutics been receiving favorable news coverage?

News stories about MRTX stock have trended neutral on Sunday, InfoTrie reports. InfoTrie identifies positive and negative media coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Mirati Therapeutics earned a daily sentiment score of 0.2 on InfoTrie's scale. They also assigned news stories about the biotechnology company a news buzz of 3.0 out of 10, indicating that recent media coverage is unlikely to have an impact on the company's share price in the near term.

Who are some of Mirati Therapeutics' key competitors?

What other stocks do shareholders of Mirati Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Mirati Therapeutics investors own include Bausch Health Companies (BHC), Micron Technology (MU), AbbVie (ABBV), Gilead Sciences (GILD), Viking Therapeutics (VKTX), Exelixis (EXEL), Anavex Life Sciences (AVXL), Pfizer (PFE), Clovis Oncology (CLVS) and Celgene (CELG).

Who are Mirati Therapeutics' key executives?

Mirati Therapeutics' management team includes the folowing people:
  • Dr. Rodney W. Lappe, Exec. Chairman (Age 64)
  • Dr. Charles M. Baum, Pres, CEO & Director (Age 61)
  • Dr. James Christensen, Chief Scientific Officer (Age 51)
  • Dr. Isan Chen, Exec. VP and Chief Medical & Devel. Officer (Age 57)
  • Mr. Jamie A. Donadio, Sr. VP & CFO (Age 44)

Who are Mirati Therapeutics' major shareholders?

Mirati Therapeutics' stock is owned by a number of of institutional and retail investors. Top institutional investors include FMR LLC (6.39%), BlackRock Inc. (5.97%), Jennison Associates LLC (3.54%), Geode Capital Management LLC (0.91%), Geode Capital Management LLC (0.91%) and Northern Trust Corp (0.80%). Company insiders that own Mirati Therapeutics stock include Aaron I Davis, Boxer Capital, Llc, Bruce L A Carter, Charles M Baum, Christopher C Lemasters, Craig A Johnson, Jamie A Donadio, Jamie Christensen, Tuesday Thirteen Inc and Venbio Select Advisor Llc. View Institutional Ownership Trends for Mirati Therapeutics.

Which major investors are selling Mirati Therapeutics stock?

MRTX stock was sold by a variety of institutional investors in the last quarter, including Barclays PLC, Broadfin Capital LLC, Dimensional Fund Advisors LP, Dimensional Fund Advisors LP, Bank of New York Mellon Corp, MetLife Investment Advisors LLC, Virtus ETF Advisers LLC and New York State Common Retirement Fund. Company insiders that have sold Mirati Therapeutics company stock in the last year include Aaron I Davis, Boxer Capital, Llc, Bruce L A Carter, Charles M Baum, Christopher C Lemasters, Craig A Johnson, Jamie A Donadio, Jamie Christensen and Venbio Select Advisor Llc. View Insider Buying and Selling for Mirati Therapeutics.

Which major investors are buying Mirati Therapeutics stock?

MRTX stock was purchased by a variety of institutional investors in the last quarter, including BlackRock Inc., Jennison Associates LLC, Perceptive Advisors LLC, Rhenman & Partners Asset Management AB, Amundi Pioneer Asset Management Inc., FMR LLC, RTW Investments LP and Squarepoint Ops LLC. Company insiders that have bought Mirati Therapeutics stock in the last two years include Boxer Capital, Llc and Venbio Select Advisor Llc. View Insider Buying and Selling for Mirati Therapeutics.

How do I buy shares of Mirati Therapeutics?

Shares of MRTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Mirati Therapeutics' stock price today?

One share of MRTX stock can currently be purchased for approximately $73.23.

How big of a company is Mirati Therapeutics?

Mirati Therapeutics has a market capitalization of $2.58 billion and generates $12.93 million in revenue each year. The biotechnology company earns $-98,420,000.00 in net income (profit) each year or ($3.19) on an earnings per share basis.

What is Mirati Therapeutics' official website?

The official website for Mirati Therapeutics is http://www.mirati.com.

How can I contact Mirati Therapeutics?

Mirati Therapeutics' mailing address is 9393 TOWNE CENTRE DRIVE SUITE 200, SAN DIEGO CA, 92121. The biotechnology company can be reached via phone at 858-332-3410 or via email at [email protected]


MarketBeat Community Rating for Mirati Therapeutics (NASDAQ MRTX)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  325 (Vote Outperform)
Underperform Votes:  220 (Vote Underperform)
Total Votes:  545
MarketBeat's community ratings are surveys of what our community members think about Mirati Therapeutics and other stocks. Vote "Outperform" if you believe MRTX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MRTX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 3/24/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel